secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641281-25-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q2 2025 loss from ops $9.2M; cash $48.5M; BDC-4182 Phase 1 ongoing
--------------------------------------------------------------------------------

- Collaboration revenue $1.8M (Q2 2024: $1.3M); R&D expenses down to $7.5M from $15.4M.
- Loss from operations narrowed to $9.2M vs $22.6M year-over-year; restructuring charges zero vs $3.6M.
- Cash, equivalents, and marketable securities $48.5M as of June 30, 2025; expected to fund operations through mid-2026.
- Next-gen claudin 18.2 ISAC BDC-4182 Phase 1 dose-escalation open; initial data expected H1 2026.
- Seeking partner for BDC-3042 after Phase 1 data; reverse stock split (1:20) done, regained Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/0001641281-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/bolt-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001641281-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer